PVCT - Provectus to get US patent for PV-10 to treat hematologic diseases

Provectus (OTC:PVCT) said the U.S. Patent and Trademark Office (USPTO) allowed a patent application covering the use of PV-10 to treat hematologic diseases. The company said the U.S. patent application 16/688,319 is titled 'Composition and Method for Treating Hematologic Cancers.' The company added that in vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls. PV-10 is a formulation of Provectus' immunogenic-small molecule and pharmaceutical-grade rose bengal sodium. Provectus (PVCT) noted that the patent would be its first  award in hematology from the USPTO. Innovate Calgary, a company of the University of Calgary, is a co-assignee and Aru Narendran of the University of Calgary’s Cumming School of Medicine is a co-inventor on the patent application.

For further details see:

Provectus to get US patent for PV-10 to treat hematologic diseases